UNSPSC 51203302: Fingolimod

This classification denotes a biological response modifier, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3QN8BYN5QF. European Medicines Agency schedules Fingolimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31908. Fingolimod generally arises in the molecular formula C19H33NO2.

The term FINGOLIMOD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, list 53.) Most nations, for tariff and trade purposes, schedule fingolimod under HS 29221980 and SITC 51461. As of Q4 2014, FINGOLIMOD remains US FDA's Preferred Term for this commodity. Fingolimod bears US NLM identifiers UMLS ID C1699926 and NCI Concept Code C74202. SMILES: CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.

UNSPSC 51203302 Fingolimod is a Commodity code that does not reflect the work actually being solicited under it in recent state and local opportunities. The recent procurement records tagged to this code document solicitations for naloxone and drug deactivation systems, medical and first aid supplies, generic pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs—none of which are fingolimod, a multiple sclerosis disease-modifying therapy. The code appears to be a classification mismatch or administrative error in the underlying procurement database, and does not support a meaningful market characterization for business development purposes.

The source contains no recent opportunities actually seeking fingolimod or other selective sphingosine-1-phosphate receptor modulators. A business development professional evaluating pursuit under this Commodity code should verify the UNSPSC classification against the actual scope of work and underlying procurement systems before committing resources, as the tagged opportunities reflect broader healthcare product procurement (naloxone, first aid supplies, generic pharmaceuticals, pharmacy benefit program design) rather than specialty pharmaceutical acquisition for a specific indication.